{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:19:01Z","timestamp":1790486341377,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5183-y","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T10:48:02Z","timestamp":1546080482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-2442","authenticated-orcid":false,"given":"Thomas J.","family":"Ettrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas W.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Perkhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Daum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Dickhut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Wittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Alg\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Gallmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Atzpodien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Kornmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Muche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Prasnikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tannapfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Reinacher-Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,29]]},"reference":[{"issue":"5","key":"5183_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277\u2013300.","journal-title":"CA Cancer J Clin"},{"key":"5183_CR2","unstructured":"Howlader N NA, Krapcho M et al: SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. SEER web site 2013."},{"issue":"11","key":"5183_CR3","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"5183_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.cell.2011.11.060","volume":"148","author":"H Haeno","year":"2012","unstructured":"Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148(1\u20132):362\u201375.","journal-title":"Cell"},{"issue":"12","key":"5183_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1055\/s-0033-1356220","volume":"51","author":"T Seufferlein","year":"2013","unstructured":"Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P, et al. S3-guideline exocrine pancreatic cancer. Zeitschrift fur Gastroenterologie. 2013;51(12):1395\u2013440.","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"3","key":"5183_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267\u201377.","journal-title":"JAMA"},{"issue":"10073","key":"5183_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011\u201324.","journal-title":"Lancet"},{"issue":"1","key":"5183_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for Resectable Gastroesophageal Cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"5183_CR9","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1245\/s10434-008-9839-8","volume":"15","author":"I Esposito","year":"2008","unstructured":"Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Buchler MW. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651\u201360.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"5183_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/archsurg.2007.17","volume":"143","author":"G Butturini","year":"2008","unstructured":"Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008;143(1):75\u201383 discussion 83.","journal-title":"Arch Surg"},{"issue":"10","key":"5183_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/bjs.5397","volume":"93","author":"CS Verbeke","year":"2006","unstructured":"Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232\u20137.","journal-title":"Br J Surg"},{"issue":"9293","key":"5183_CR12","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","volume":"358","author":"JP Neoptolemos","year":"2001","unstructured":"Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576\u201385.","journal-title":"Lancet"},{"issue":"8","key":"5183_CR13","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/sj.bjc.6602513","volume":"92","author":"DD Stocken","year":"2005","unstructured":"Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92(8):1372\u201381.","journal-title":"Br J Cancer"},{"key":"5183_CR14","unstructured":"Network NCC: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, Version 2\/2017. In.; 2017."},{"issue":"2","key":"5183_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/1097-0142(20000715)89:2<314::AID-CNCR16>3.0.CO;2-V","volume":"89","author":"H Snady","year":"2000","unstructured":"Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000;89(2):314\u201327.","journal-title":"Cancer"},{"issue":"10","key":"5183_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00268-004-7338-z","volume":"28","author":"R Wilkowski","year":"2004","unstructured":"Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg. 2004;28(10):1011\u20138.","journal-title":"World J Surg"},{"issue":"13","key":"5183_CR17","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1200\/JCO.2008.19.7921","volume":"27","author":"F Huguet","year":"2009","unstructured":"Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27(13):2269\u201377.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5183_CR18","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.","journal-title":"PLoS Med"},{"key":"5183_CR19","doi-asserted-by":"crossref","unstructured":"Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L et al: nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015, 107(2).","DOI":"10.1093\/jnci\/dju413"},{"issue":"18","key":"5183_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"key":"5183_CR21","doi-asserted-by":"crossref","unstructured":"Hosein PJ, Kawamura C, Macintyre J, Loaiza-Bonilla A, Merchan JR, Levi JU, Rocha Lima CS: Pilot study of neoadjuvant FOLFIRINOX in unresectable locally advanced pancreatic carcinoma. J Clin Oncol 2011, 29(ASCO MEETING ABSTRACTS Feb 3, 2011:324).","DOI":"10.1200\/jco.2011.29.4_suppl.324"},{"issue":"19","key":"5183_CR22","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"6","key":"5183_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801\u201310.","journal-title":"Lancet Oncol"},{"issue":"4","key":"5183_CR24","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/bjc.2013.415","volume":"109","author":"R Alvarez","year":"2013","unstructured":"Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Munoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109(4):926\u201333.","journal-title":"Br J Cancer"},{"issue":"15_suppl","key":"5183_CR25","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1200\/jco.2015.33.15_suppl.4115","volume":"33","author":"A Barbour","year":"2015","unstructured":"Barbour A, O'Rourke N, Chandrasegaram MD, Chua YJ, Kench J, Samra JS, Pavlakis N, Haghighi KS, Yip S, Fawcett J, et al. A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study. Journal of Clinical Oncology. 2015;33(15_suppl):4115.","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"5183_CR26","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1200\/jco.2013.31.15_suppl.4038","volume":"31","author":"S MacKenzie","year":"2013","unstructured":"MacKenzie S, Zeh H, McCahill LE, Sielaff TD, Bahary N, Gribbin TE, Seng JE, Leach JW, Harmon J, Demeure MJ, et al. A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC). Journal of Clinical Oncology. 2013;31(15_suppl):4038.","journal-title":"Journal of Clinical Oncology"},{"key":"5183_CR27","doi-asserted-by":"crossref","unstructured":"Shawn MacKenzie HZ, Laurence E. McCahill, Timothy D. Sielaff, Nathan Bahary, Thomas Edward Gribbin, John E. Seng, Joseph W. Leach, Jocelyn Harmon, Michael J. Demeure, Daniel D. Von Hoff, A Jim Moser, Ramesh K. Ramanathan: A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC). J Clin Oncol 2013, 31, 2013 (suppl; abstr 4038).","DOI":"10.1200\/jco.2013.31.15_suppl.4038"},{"issue":"34","key":"5183_CR28","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Hoff Von","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol. 2011;29(34):4548\u201354.","journal-title":"J Clin Oncol"},{"issue":"6","key":"5183_CR29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","volume":"32","author":"JW Valle","year":"2014","unstructured":"Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504\u201312.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5183_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jso.21469","volume":"101","author":"DE Abbott","year":"2010","unstructured":"Abbott DE, Baker MS, Talamonti MS. Neoadjuvant therapy for pancreatic cancer: a current review. J Surg Oncol. 2010;101(4):315\u201320.","journal-title":"J Surg Oncol"},{"key":"5183_CR31","volume-title":"Statistical models and methods for lifetime data","author":"JF Lawless","year":"1982","unstructured":"Lawless JF. Statistical models and methods for lifetime data. New York: Wiley; 1982."},{"issue":"5","key":"5183_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"5183_CR33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0959-8049(99)00047-7","volume":"35","author":"D Fitzsimmons","year":"1999","unstructured":"Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, Buchler MW, Dervenis C, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC study group on quality of life. Eur J Cancer. 1999;35(6):939\u201341.","journal-title":"Eur J Cancer"},{"issue":"2","key":"5183_CR34","first-page":"83","volume":"41","author":"C Herrmann","year":"1991","unstructured":"Herrmann C, Scholz KH, Kreuzer H. Psychologic screening of patients of a cardiologic acute care clinic with the German version of the hospital anxiety and depression scale. Psychother Psychosom Med Psychol. 1991;41(2):83\u201392.","journal-title":"Psychother Psychosom Med Psychol"},{"issue":"6","key":"5183_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"5183_CR36","doi-asserted-by":"crossref","unstructured":"Neoptolemos JP, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J, Meyer T, Anthoney A, Glimelius B, Falk S et al: ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 2016, 34(2016 (suppl; abstr LBA4006)).","DOI":"10.1016\/j.pan.2016.05.215"},{"issue":"8","key":"5183_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamasurg.2015.0668","volume":"150","author":"A Paniccia","year":"2015","unstructured":"Paniccia A, Hosokawa P, Henderson W, Schulick RD, Edil BH, McCarter MD, Gajdos C. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg. 2015;150(8):701\u201310.","journal-title":"JAMA Surg"},{"issue":"2","key":"5183_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.23174","volume":"112","author":"DS Zuckerman","year":"2008","unstructured":"Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer. 2008;112(2):243\u20139.","journal-title":"Cancer"},{"key":"5183_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/1471-2407-11-346","volume":"11","author":"S Heinrich","year":"2011","unstructured":"Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine\/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 2011;11:346.","journal-title":"BMC Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5183-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:21:34Z","timestamp":1605918094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5183-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5183"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5183-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"11 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee of Ulm University approved the NEONAX-trial as leading ethics committee for all German sites. In addition, local ethics committees approved the participating sites. The trial is registered with(NCT02047513) and the European Clinical Trials Database (2013\u2013005559-34). All patients signed informed consent according to GCP.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Gemcitabine and nab-Paclitaxel were provided by Celgene. Otherwise, the authors declare no conflicts of interest. The trial was sponsored by Celgene.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1298"}}